Rapid health technology assessment of calcitonin in the treatment of postmenopausal osteoporosis
- VernacularTitle:降钙素治疗绝经后骨质疏松症的快速卫生技术评估
- Author:
Zihui ZHENG
1
,
2
;
Feng GAO
3
;
Yatong ZHANG
1
,
2
;
Zinan ZHAO
1
,
2
;
Huijie PAN
2
,
4
;
Liwei JI
1
,
2
;
Xin HU
1
,
2
;
Pengfei JIN
1
Author Information
1. Dept. of Pharmacy，Beijing Hospital/Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application （Beijing Hospital ），Beijing 100730，China
2. National Center of Gerontology/ Institute of Geriatric Medicine，Chinese Academy of Medical Sciences，Beijing 100730，China
3. Dept. of Health Service，the Guard Bureau of the Joint Staff Department of Chinese PLA，Beijing 100017，China
4. Dept. of Laboratory，Beijing Hospital，Beijing 100730，China
- Publication Type:Journal Article
- Keywords:
calcitonin;
postmenopausal osteoporosis;
health economics;
rapid health technology assessment
- From:
China Pharmacy
2022;33(21):2654-2659
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE According to the rapid Health Technology Assessment （HTA） for postmenopausal osteoporosis （PMOP），To evaluate the efficacy ，safety and economy of calcitonin in the treatment of PMOP ，and provide evidence -based medical evidence for clinical drug decision . METHODS Retrieved from the Cochrane Library ，PubMed，Embase，CNKI，Wanfang database，CBM and HTA official website ，systematic review/meta -analysis，pharmacoeconomics research and HTA reports about calcitonin in the treatment of PMOP were retrieved from the inception to Sept . 30th，2022. Two researchers independently carried out screening ，data extraction and quality evaluation ，and analyzed the data results descriptively . RESULTS A total of 18 studies were included ，including 12 SR/meta-analysis and 6 economic studies ，and no HTA report was retrieved . In terms of effectiveness ， the results of the included studies were basically consistent ：calcitonin had a certain advantage in reducing the incidence of vertebral fracture compared with calcium and lasoxifene alone ，but did not show clinical advantage compared with other positive drugs . In terms of reducing the incidence of non -vertebral fractures ， calcitonin had some advantages ，compared with calcium al one and raloxifene ，but did not show clinical advantage compared with other positive drugs . In terms of improving bone mineral density（BMD），only 2 studies showed that calcitonin had a certain advantage over calcium but no advantage was observed compared with other positive drugs . In terms of improving non - vertebral BMD ，only 1 study showed that calcitonin combined with calcium had certain advantages compared with calcium alone in improving femoral BMD ，but there was no advantage compared with other positive drugs . In terms of lowering bone pain scores ， both included studies demonstrated short -term benefit of nasal calcitonin in reducing acute pain was found in patients with vertebral fractures，but not in patients with chronic pain . In terms of safety ，the three included studies showed that calcitonin caused mild adverse reactions compared with other positive drugs ，but there was a risk of malignant tumors after long -term use . In terms of economy，only 1 study showed the use of nasal calcitonin in the treatment of PMOP had more economic advantages than no treatment or etidronate . CONCLUSIONS Calcitonin has a certain effect on reducing acute pain in patients with PMOP vertebral fracture，and its safety needs further investigation . No obvious economic advantage has been found .
